At the time of writing, Protagonist Therapeutics Inc [PTGX] stock is trading at $41.44, down -0.26%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PTGX shares have gain 2.09% over the last week, with a monthly amount drifted -1.07%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Protagonist Therapeutics Inc [NASDAQ: PTGX] stock has seen the most recent analyst activity on October 30, 2023, when CapitalOne initiated its Overweight rating and assigned the stock a price target of $32. On August 25, 2022, JMP Securities initiated with a Mkt Outperform rating and assigned a price target of $21 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $55 on February 11, 2022. JP Morgan upgraded its rating to a Overweight and raised its price target to $55 on October 12, 2021. Northland Capital upgraded its rating to Outperform for this stock on October 11, 2021, but kept the price target unchanged to $40. In a note dated September 20, 2021, JP Morgan downgraded an Neutral rating on this stock and revised its target price from $60 to $49.
For the past year, the stock price of Protagonist Therapeutics Inc fluctuated between $13.72 and $42.67. Currently, Wall Street analysts expect the stock to reach $38 within the next 12 months. Protagonist Therapeutics Inc [NASDAQ: PTGX] shares were valued at $41.44 at the most recent close of the market. An investor can expect a potential drop of -8.3% based on the average PTGX price forecast.
Analyzing the PTGX fundamentals
Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at 0.48%, Pretax Profit Margin comes in at 0.54%, and Net Profit Margin reading is 0.53%. To continue investigating profitability, this company’s Return on Assets is posted at 0.28, Equity is 0.85 and Total Capital is 0.27. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 40.80 points at the first support level, and at 40.16 for the second support level. However, for the 1st resistance point, the stock is sitting at 42.17, and for the 2nd resistance point, it is at 42.90.
Ratios To Look Out For
It is important to note that Protagonist Therapeutics Inc [NASDAQ:PTGX] has a current ratio of 13.73. Also, the Quick Ratio is 13.73, while the Cash Ratio stands at 8.55. Considering the valuation of this stock, the price to sales ratio is 7.65, the price to book ratio is 4.50 and price to earnings (TTM) ratio is 15.77.
Transactions by insiders
Recent insider trading involved Waddill William D., Director, that happened on Jul 24 ’24 when 8000.0 shares were sold. Director, Waddill William D. completed a deal on Jun 07 ’24 to sell 8000.0 shares. Meanwhile, President and CEO PATEL DINESH V PH D sold 35000.0 shares on Jun 07 ’24.
